SUBJECT INDEX

A

Acetylcholine receptor, 401
  See also Nicotinic acetylcholine receptor
Acetylcholine receptor–inducing activity (ARIA), 401
Acquired immunodeficiency syndrome (AIDS)
  AIDS dementia complex (ADC), 222
  microglia response and, 221
Activins
dorsal patterning and, 288
Adenosine triphosphate (ATP), 445, 472–74
  ATP-activated P2X receptors, 472–74
    corelease with ACh, 445
Adherens junctions, 11, 13, 18–20
  blood-brain barrier and, 11, 13, 18–30
  cadherins and, 19
  catenins and 19–20
  tight junctions and, 18
Adrenal steroids
  hippocampal plasticity and, 106, 114–18
    hippocampal atrophy and, 114–18
  neurogenesis in dentate gyrus and, 106
Adrenocorticotropin secretion, 105
Aggression
  monoamine oxidase A deficiency and, 198, 200
Aging, 105, 116–18, 123–39
  hippocampal plasticity and, 105, 116–18
  Parkinson's disease and, 123–39
Agrin
  AChR clustering in neuromuscular junction and, 395–404
    rapsyn and, 399–400
  signaling, 398–400
    MuSK and, 398–400
AIDS dementia complex (ADC), 222
Alcoholism
  monoamine oxidase and, 208–9
Alzheimer's disease, 90–91, 125–26, 219, 221, 231–34
  microglia and, 219, 221, 231–34
  nonsteroidal anti-inflammatory drug treatment of, 234
Amacrine
  retinal waves and, 35
α-Amino-3-hydroxy-5-methylisoxazole-4-proprionic acid (AMPA), 465–68
AMPA receptors, 465–68
Amygdala, 106
Amyloid plaques, 231–34
Amyloid precursor protein (APP), 231–34
Antigen-presenting cell, 230
Anti-G-protein coupled receptor antibodies, 188–89
Anti-synaptotagmin, 182
Apoptosis
  apoptosis initiating factors, (AIFs), 135–36
  dentate gyrus granule neuron, 112–14
  mitochondria and, 135–36
  Parkinson's disease and, 134–38
  See also Cell death
Arachidonic acid, 227–28
  HIV dementia and, 228
Attention
  visuospatial, 319–47
    lateral intraparietal (LIP) area and, 321–22, 328–47
    parietal cortex and, 319–47
Audition
  human speech and birdsong, 575–79
Autoantibodies
  modulation of synaptic transmission by, 175–92
    anti-synaptotagmin, 182
    anti-G-protein coupled receptor antibodies, 188–89
    autoantibodies to GluR3, 185–87
    blood-brain barrier and, 176, 187
    nicotinic cholinergic receptors (nAChR) and myasthenia gravis, 178–80
    voltage-dependent calcium channel and, 180–84
    voltage-dependent potassium channel and, 183–84
Autoimmunity
  synaptic transmission and, 175–92
    blockade of calcium channels and, 180–83
    blood-brain barrier and, 176, 187, 189–92
    environmentally induced modification of self proteins, 177
    epitope or determinant spreading, 177, 185
    molecular mimicry and, 176, 185, 188
    paraneoplastic syndromes, 177, 181, 183
    superantigen–T-cell interactions and, 176
Axonal guidance, 351–80
  Comm and, 373
  Eph receptors and, 375–80
  ephrins and, 375–80
  growth cone signal transduction and, 351, 354–81
  hepatocyte growth factor/scatter factor, 374
  L1 and, 374–75
  netrins and, 364–72
    attractive receptors, 368–69
    cAMP levels and, 370–72
    netrin-1-mediated chemoattraction and chemorepulsion, 370–72
    repulsive receptors, 369–70
  neuropilins and, 360–62
  Rho-GTPases and, 351, 354–59
  ROBO and, 372–74
  semaphorins and, 359–64
    function, 364
    signal transduction mechanisms of, 364
  Sif and, 356
Axonogenesis, 354

B

Basal ganglia, 49
Basic helix-loop-helix transcription factor (bHLH), 518, 543–44
Behavior
  aggression
    monoamine oxidase A deficiency and, 198, 210
  vision and
    functional magnetic resonance imaging and, 145, 150, 163–64

Bilateral periventricular nodular heterotopia, 530, 533
Birdsong, 567–621
  definition, 569–71
  neural substrates for, 596–609
    lateralization, 606, 608–9
  sensitive learning periods, 609–10, 612–19
    hormones and, 614
    neural mechanisms, 618–19
    sensory experience, 614–17
    social factors, 617–18
  structure, 571–73
  vocal learning and, 573–79
    audition and, 575–79
    vocal production and, 592–93
Blood-brain barrier, 11–25, 176, 187, 189–92, 223
  astrocytes and, 15–17
  autoantibodies to GluR3 and, 187
  autoimmune diseases and, 176, 187, 189–92
  cell culture models, 15–18
  development, 13–14
    microenvironment and specificity, 14
  endothelial cells and, 11–25
  HIV infection and, 223
  myelin-reactive T cells and, 176
  pathological regulation of, 23–24
  stress and permeability of, 25
  tight junctions and, 11–25
Blood oxygenation
  activity-dependent
  functional magnetic resonance imaging and, 145–70
Bone morphogenetic protein (BMP), 261–65, 272–89
  dorsal interneuron generation and, 277–80
  family, 546
  signaling, 263–65, 272–89
    dorsal cell fate and, 263–65, 272–89
    neural induction and, 265, 272–89
Brain capillary endothelial cells, 11–25
Brain-derived neurotrophic factor (BDNF), 132, 296–310
  Parkinson's disease and, 132
  synaptic plasticity and, 296–310
    LTD and, 299–300, 302
    LTP and, 299–300, 302
Brain lipid protein (BLBP)
  cell migration and, 514–15, 520
Brain regions
  establishment of, 512–13
    anterior-posterior (AP) axis, 512
    dorso-ventral (DV) axis, 512

C

Cadherins, 19
Cadherin 6B, 275
Calcitonin-related peptide (CGRP), 400–1
  synapse-specific transcription, 400–1
Calcium channels
  FM dye studies of, 5
  neurite, 5
  somatic, 5
cAMP, 17–18, 21
  blood-brain barrier permeability and, 17–18, 21, 23
cAMP responsive element binding protein (CREB), 299
Catenin, 19–20, 22
  β, 20, 22
Cell adhesion
  cadherin-dependent, 18
Cell-cell adhesion molecules, 18
Cell death, 30
  synapse elimination, 30
  See also Apoptosis
Cell migration, 511–34
  brain lipid protein and, 514
  cerebellar cortex and, 511–18
  embryogenesis, 513
  glial guided
    astrotactin and, 511
    erbB and, 511
    glial growth factor and, 511
    molecular mechanisms of, 521–23
  hippocampal formation and, 511
  human cell migration disorders, 529–34
  mutations, 511, 516–17, 525–27, 530–34
  neuronal migration, 513–34
  olfactory bulb and, 511–12, 528–29
  radial glial scaffold, 514–15
  radial pathway, 513
  tangential migration in cerebral cortex, 525–26
  three-step development, 512
Centrifugal fibers in sensory systems, 56–58
  avian brain, 57–58
Cerberus, 263
Cerebellar cortex
  Bergman glial cells of, 514
    BLBP expression of, 514
    GFAP expression of, 514
  development of, 515–18
  glial guided cell migration, 511–12
Cerebellum
  external granule layer (EGL), 527–28
  subventricular zone (SVZ), 527–29
Cerebral cortex
  electron microscopy, 81–87
  intrinsic connections, 87–88
  pathways for sensory convergence, 49, 71–78
Chagas' disease, 176–77, 188
Chordin, 263, 273
Ciliary neutrophic factor
  Parkinson's disease and, 132
Cloning, 197, 200, 204
  monoamine oxidase
    human liver, 200
    trout liver, 204
  odorant receptor genes, 488–89
  reeler gene, 516
Collapsin-1
  axonal guidance and, 357, 359–64
Collapsin response mediator protein (CRMP-62), 364
Color perception
  color tuning within a cortical region, 163
  functional MRI and, 145, 161–63
  opponent-colors signals and, 161–63, 170
Connexins, 19
ω-Conotoxin MVIIC, 5
Corticofugal connections, 49, 56–58
Countermanding paradigm, 241, 253
CREB, 299
Cushing's syndrome, 116–17
Cyclic AMP
  See cAMP
Cyclic nucleotide-gated channels, 471–72
Cytokines, 219, 227

D

Dementia, 116–17
  AIDS dementia complex, 222
  HIV dementia, 221–29
    microglial infection and, 22
Dendrites, 105, 107–12
  atrophy of
    stress and, 107–12

Dentate gyrus, 105–8, 111–14, 116–18
  balance between aptosis and neurogenesis in, stress and, 113–14, 116–18
Dopamine
  neurons
    6-OHDA, 128–29
  release in striatum
    nAChRs and, 461–62
Dorsal lateral geniculate nucleus (dLGN), 30–32, 37–41
  activity-dependent formation of eye-specific layers, 31–32, 37–41
Dorsal neural fates, 261–89
  activins and, 288
  bone morphogenetic protein (BMP) signaling and, 263–65, 272–89
  glial-derived neurotrophic factor (GDNF) and, 288
  regulation in midbrain and forebrain, 285–87
  specification in hindbrain, 281–83
  transforming growth factor-β and, 262, 269, 272–73, 276–89
Dorsoventral patterning, 261–89
Drosophila
  synaptogenesis in, 390
Dyslexia
  functional MRI studies of, 145, 164, 170
  magnocellular pathway abnormality, 164, 170

E

Electron microscopy
  cerebral cortex, 81–82, 85–87
  of CNS, 78–81
  olfactory bulb, 81–85
  striatum, 81
  thalamus, 81–83, 86–87
Embryogenesis, 513–34
End plate potentials (EPPs), 3
Endocytosis, 1–7
  FM studies of, 1–7
Endothelial cells, 11–25
  brain, 11–25
    blood-brain barrier and, 11–25
    cAMP levels and, 17–18, 21
    cell biology of, 13
    specific membraine transporting proteins and, 12
Epidermal growth factor–related (erbB) receptor, 402
Epitope spreading, 177, 185
  Rasmussen's encephalitis, 185
Excitatory amino acid (EAA) release
  stress and, 110
Exocytosis, 1–7
  modulation of
    ATP and, 7
    CA^{2+} release and, 7
    calcineurin and, 3
    calcium and, 5
    nitric oxide (NO) and, 3
    staurosporin and, 4
Experimental allergic encephalomyelitis (EAE), 230
Experimental autoimmune encephalomyelitis (EAE), 177
Extracellular matrix (ECM)
  cell migration and, 517, 521, 523
Eye field, 241

F

Fibroblast growth factor (FGF), 132, 261, 264, 269–70
  neural crest induction and, 269–70
  Parkinson's disease and, 132
Fibroblasts, 353–54
Fluorescence-activated cell sorter (FACS), 7
Fluorescence microscopy (FM), 1–7
  exocytosis and endocytosis, 1–7
  neurotransmitter release, 5
  reinervation, 1, 6, 7
  synaptic transmission, 1, 4–6
  synaptogenesis, 1
  vesicle recycling, 2–4
  wound healing, 6, 7
Fluorescence recovery after photobleaching (FRAP), 4
FM1-43 fluorescent probe, 1–7
  double-bond bridge, 2
  reinervation, 1, 6, 7
  synaptic transmission, 1, 4–6
  synaptogenesis, 1
  wound healing, 6, 7
Frontal eye field (FEF), 244–56
  gaze control signals in, 253–56
  saccadic eye movements and, 244
  target selection
    during visual masking, 247–48
    during visual search, 245–47
    experience and, 248–49
    timecourse, 249–51
Follistatin, 263–64, 273, 277
Fovea
  scanning eye movements and, 242–43
Functional magnetic resonance (fMRI), 145–70
  blood oxygen–level dependent (BOLD) signal
    identifying vascular source of, 149–50
    neural control signals of, 147–49
  computations, 165–69
  dyslexia studies with
    magnocellular pathway abnormality, 145, 164, 170
  signal-to-noise ratio, 146, 158, 163
    spatiotemporal resolution of, 149–50
  visual cortex, 145, 150–70
    behavioral correlations, 145, 150, 163–64
    color response, 150, 161–63
    motion response, 150, 156–60
    retinal image motion, 159–60
    retinotopy, 150–52
    traveling wave measurements, 152–53, 155
    visual area identification, 150, 155–56

G

GABA, 443
GABA-gated Cl channels, 443–45, 475–76
  presynaptic ionotropic $GABA_A$ receptors, 448–54
    crayfish neuromuscular junction and, 449–51
Gaze control, 241–56
  frontal eye field and, 253–55
GFAP
  cell migration and, 514–15
Glial cell like–derived neurotrophic factor (GDNF), 543
Glial cells
  Bergman, 514
  radial, 514
Glial-derived neurotrophic factor (GDNF)
  dorsal patterning and, 288
  Parkinson's disease and, 132

Glial growth factor
cell migration and, 514
Gliosis, 52–55, 64
Glutamate
retinal waves and, 35
P-Glycoprotein, 12
Glucocorticoids, 105–6, 108, 114–18
aging and, 105, 116–18
Cushing's syndrome and, 116–17
dementia and, 116–17
hippocampal atrophy and, 114–18
hippocampal plasticity and, 105–6
stress-induced dendritic atrophy and, 109–10
recurrent depressive illness, 116–17
schizophrenia, 116–17
Glutamate
GluR3
autoantibodies to, 185–87
Rasmussen's encephalitis and, 185–87
presynaptic glutamate receptors, 465–71
release from limbic structure nAchRs and, 462–63
Glutathione (GSH), 127–29, 131
butathione sulphoximine and, 128
neurogeneration in Parkinson's disease and, 127–29, 131
gp120, 227
G-protein-coupled receptors
agonist antibodies and, 175
autoantibody-mediated CNS diseases, 188–89
Chagas' disease, 188–89
experimentally produced anti-GPCR antibodies, 189
G protein–gated inwardly rectifying potassium channel, 526
Granule cell
identity, 518–20
migration along glial fibers, 520–21
Gremlin, 263
Growth cones, 351–80
actin filaments, 353
collapsin-1, 357, 359
filopodia, 353–59
Cdc42, 354, 356–59
Rac, 354–59
Rho, 354–59
lamellipodia, 353
lysophosphatic acid (LPA), 356, 358
growth cone collapse and, 358
microtubules, 353
segmental nerve, 356
signal transduction, 351, 354–80
cAMP and, 353, 370–72
GTPase-activating proteins (GAPs) and, 355
guanine nucleotide dissociation inhibitors (GDIs) and, 355
guanine nucleotide exchange factors (GEFS), 355
myosin light-chain phosphatase (MLCP), 355, 358, 364
Rho-GTPases and, 351, 354–59
Guanine nucleotide exchange factors (GEFs), 355

H

Hebb's postulate, 32, 39
Hepatocyte growth factor (HGF), 549–51
Hippocampal plasticity
stress and, 105–18
glucocorticoids and, 105–6, 108–10
hippocampal atrophy and, 114–18
NMDA receptors and, 105–12
reversible atrophy of dendrites and, 107–12
synaptic vesicle reorganization in mossy fiber terminals and, 110–11
Hippocampus, 105–18
adrenocorticotropin secretion and, 105
atrophy of, 114–18
glial guided cell migration and, 511–12
mineralocorticoid secretion and, 106
spatial learning and memory and, 105–18
stress hormones and, 105–18
HIV dementia (HIVD)
microglial infection and, 221–29
arachidonic acid and, 228
nitric oxide and, 227–28
quinolinic acid and, 228
HIV encephalitis (HIVE), 222
Human immunodeficiency virus (HIV), 221–29
microglia and
CCR5 receptor and, 226
CD4 receptor and, 225–26
CXCR4 receptor and, 226
HIV entry into CNS, 223–24
HIV persistence in CNS, 224–25
Human speech, 567–621
definition, 569–71
neural substrates for, 596–609
sensitive learning periods, 609–12
structure, 571–73
vocal learning and, 573–79, 592–96, 609–19
audition and, 575–79
vocal production and, 592–95
6-Hydroxydopamine (6-OHDA), 128–29

I

Immunoglobin G, 178–79, 181
Isaac's syndrome
See Neuromyotonia

J

JC virus, 221

K

Kainate receptors, 465, 468–71
Knock-out mice
monoamine oxidase research with, 197–98, 206, 210–12

L

Lambert-Eaton myasthenic syndrome (LEMS), 180–83, 190
Lateral intraparietal (LIP) area of parietal cortex, 321–22, 328–47
spatial representation in, 321–22, 328–47
neural signals in LIP and, 329–38
remapping, 342–43, 346
Learning, 573–619
audition and, 575–79
experience and, 584–92
innate predispositions, 579–84
perception and, 592–96
sensitive periods for, 609–19
hormones and, 614
neural mechanisms, 618–19
sensory experience, 614–17
social factors, 617–19

vocal learning in humans and songbirds, 573–79, 592–96, 609–19
Levodopa, 123, 129
Lewy bodies, 123, 128
Lissencephaly, 530, 532–34
Long-term depression (LTD)
brain-derived neurotrophic factor mRNA levels and, 299–300, 302
Long-term potentiation (LTP)
brain-derived neurotrophic factor mRNA levels and, 299–300, 302
stress and, 106, 111–12
Lysophosphatidic acid (LPA), 21, 23, 356, 358
growth cone collapse and, 358

M

Malondialdehyde, 129
Marchi technique, 50
MASH1, 543–46
Math1, 518–20
MDCK cells, 18
Membrane-associated guanylate kinase protein family, 19
Membrane attack complex, 187
Memory
hippocampal plasticity and, 105–18
stress and, 105–18
adrenal steroids and, 106, 114–18
dentate gyrus volume and, 113–14
hippocampal atrophy and, 114–18
N-Methyl-D-aspartate
See NMDA
1,2,3,6-Methyl-phenyl-tetrahydropyridine (MPTP)
Parkinson's disease and, 124, 126, 128–31, 133, 137, 139
Microglia, 219–35
Alzheimer's disease and, 219, 221, 231–34
HIV and, 219, 221–29
entry into CNS of, 223–24
viral persistence in CNS of, 224–25
HIV dementia and, 221–29
HIV-infected, 219–29
leptomeningeal macrophages, 219
multiple sclerosis and, 219, 221, 229–31
neuronal injury and, 226–27
parenchymal, 219
perivascular, 219
tumor necrosis factor alpha release and, 221
Mitochondria
apoptosis and, 135–36
Molecular mimicry, 176, 185, 188
Monoamine oxidase (MAO), 197–212
alcoholism and, 208–9
genes, 200–6
catalytic activity and, 198, 202–4
DNA sequence responsible for transcription activation, 201–2
imidazole binding, 198
localization and development, 198–200
MAO-A deficiency
aggression and, 198, 210
Parkinson's disease and, 198
smoking and, 208–9
stress-related disorders, 209
subtypes A and B, 198
Monooxidase type B (MAO-B), 124
Mossy fiber terminals
synaptic vesicle reorganization in
stress and, 110–11
Motion perception, 145, 156–60
motion-responsive region of brain
functional MRI of, 156–60
motion contrast-response fuctions, 158–59
retinal image motion, 159–60
Motor neuron, 390–94
Multiple sclerosis, 24, 176–77, 219, 221, 229–31
blood-brain barrier and, 24
experimental autoimmune encephalomyelitis (EAE) and, 177
microglia and, 229–31
superantigen–T-cell interactions and, 176
Muscle fiber, 390–94
MuSK, 398–400, 404, 428
agrin signaling and, 398–400, 404
interactions with rapsyn, 399–400

N

Nerve growth factor (NGF)
Parkinson's disease and, 132
synaptic plasticity and, 296–310
Neural crest, 261–89, 393, 542–48
induction
bone morphogenetic protein signaling and, 263–65, 272, 280
fibroblast growth factor and, 261, 264, 269–70
transforming growth factor-β and, 261–62, 269, 272–73
Wnt and, 261, 269–72
Schwann cells derived from, 393
sympathetic neurons from specification and differentiation of, 542–48
Neural patterning, 261–89
bone morphogenetic protein (BMP) signaling, 261, 263–65, 272–89
TGFβ and, 263
Neuregulin
signaling, 402, 404
synapse-specific transcription and, 400–1
Neurogenesis, 105–14, 261–89, 511
dentate gyrus, 105–8, 111–14
dorsal cell fates and, 261–89
secondary, 511
Neuroimaging
computational
See Functional magnetic resonance
Neuromuscular junction
crayfish, 449–51
formation, 393–411, 422–28
frog, 2–4
motor neurons, 390–94
muscle fiber, 390–94
postsynaptic differentiation, 395–404
AChR clustering and, 395–404
activity signaling, 403–4
extrasynaptic repression, 402–3
presynaptic differentiation, 404–7
Schwann cell, 390–94
structure and molecular architecture, 390–93
synapse
elimination, 389, 411–16
formation, 389–411, 422–28
maintenance, 389, 416–19
regeneration, 389, 419–22
Neuromyotonia, 183–84, 190
channel proteins bound by immunoglobin G, 184
voltage-dependent potassium

channel blockade and, 183–84
Neuronal degeneration
endogenous microglial products and, 227–29
Neuronal differentiation, 541–60
Neuronal injury
HIV infection
microglia and, 226–27
Neuronal migration, 513–34
glial guided, 511–34
disorders, 529–34
bilateral periventricular nodular heteropia (BPNH), 530, 533
lissencephaly, 530, 532–34
Zellweger syndrome, 531–33
Neurotransmission
antibody modulation of, 175–92
Neurotransmitter
plasticity, 555–60
regulation of phenotype, 555–60
release
quantal analysis, 5
Neurotrophic factors/neurotrophins
axonal branching and, 304–5
brain-derived (BDNF), 132, 296–310, 552
ciliary (CNTR), 132
dendritic form, 305–6
distribution, 297–98
excitability and, 302–3
expression
activity and, 298–300
fibroblast (FGF), 132
glial-derived (GDNF), 132, 543
nerve growth factor (NGF), 132, 296–310, 548–49
neurotrophin-3 (NT-3), 296–310, 549–51
LTD and, 302
LTP and, 302
neurotrophin-4/neurotrophin-5 (NT-4/5), 296–310
receptors
p75, 296
tyrosine kinase (trk), 296–310
retrograde and anterograde actions, 308–9
secretion
activity and, 300
spatial and temporal specificity, 309–10
sympathetic neuron development and, 541, 548–54
Neurturin (NTN), 550
Nicotinic cholinergic receptor (nAChR), 178–80, 389–92, 395–404, 443, 445–65, 475–76
antibodies against, 178–80
autoreceptors, 460–61
clustering, 395–404
agrin and, 396–404
heterosynaptic modulation, 461–63
dopamine release in striatum, 461–62
glutamate release from limbic structures, 462–63
localization on presynaptic terminals, 454–55
modulation of transmitter release, 455–60
neuromuscular junction and, 389–92, 395–404
synaptic elimination, 411–16
synaptic maturation, 407–11
presynaptic, 443, 445–65
Nitric oxide, 16, 227–28
blood-brain barrier and, 16
NMDA, 131
NMDA receptors, 105–12, 443, 465–71
hippocampal plasticity and, 105–12
reversible atrophy of dendrites and, 107–12
Noggin, 263–65, 273, 277
Non-amyloid component precursor protein (NACP), 126
Non-beta amyloid component (NAC), 125

O

Occludin, 11, 18–21
phosphorylation of, 11, 23
Ocular dominance columns
neurotrophins and, 306–8
visual experience and, 31–32
Odorant receptor (OR) genes
cloning of, 488–89
expression, 495
axon guidance, 497
glomerular convergence, 487–88, 497–99, 504–5
onset of, 496–97
protein, 499
in testes, 499–500
gene family, 489–94
open reading frames (ORFs) of, 489–93
regulation, 500–2
Okadaic acid, 4
Olfaction, 487–88, 502–5
Olfactory bulb, 487, 495–99
glial guided cell migration, 511–12
glomerular convergence, 487–88, 497–99
migration of subventricular zone cells into, 528–29
Olfactory sensory neurons (OSNs), 488, 494–95
distribution, 495–96
G-protein–dependent elevation of cAMP and, 488
number of genes expressed per, 501–2
Olfactory system, 49, 67–69
Oxidative damage
Parkinson's disease and, 129
Oxidative stress, 123, 127–30
glutathione deficiency and, 127–29
iron accumulation and, 127–28
Parkinson's disease and, 127–30
reactive oxygen species, 127–28

P

p75, 296
$p75^{NTR}$, 551–53
brain-derived neurotrophic factor and, 552
p120
junctional permeability, 22–23
Paraneoplastic syndromes, 177, 180–84
Lambert-Eaton myasthenic syndrome, 180–83
neuromyotonia, 183–84
Parkinson's disease, 123–39, 198, 207–8, 211
apoptosis and, 134–37
versus necrosis, 134
controlling, 137–39
selegiline, 138
etiology, 123–24
excitotoxicity and, 130–31
nitric oxide and, 131
NMDA and, 131
genetic factors, 124–26
immune model of, 133–34
Lewy bodies, 123
mitochondrial dysfunction, 129–30
monoamine oxidase B and, 198, 207–8, 211
MPTP toxicity and, 124, 126, 128–31
neurotrophic factors and, 132
oxidative damage and, 129
oxidative stress and, 127–29

substantia nigra and, 125, 127–28
mitochondrial complex I defect in, 125, 129–30
α-synclein mutation, 125–26
Parietal cortex, 319–47
spatial representation in, 319–47
anterior intraparietal area, 321, 328
lateral intraparietal area, 321–22, 328–47
medial intraparietal area, 321–22, 325, 328
multiple spatial reference frames of, 320
parieto-occipital area of, 321
posterior intraparietal area, 321
sensory-to-motor coordinate transformation, 319
ventral intraparietal area, 321–25
Perception
color
color tuning within a cortical region, 163
functional MRI and, 145, 161–63
opponent-colors signals and, 161–63, 170
vocal learning and, 592–96
vocal production and, 592–96
Phagocytosis, 7
Phenytoin, 107, 116
Phosphorylation
occludin, 23
tyrosine, 21–22
Phox2a, 543–48
Phox2b, 544
Pia mater, 14
Plasticity
dendritic, 107–12
developmental, 303–8
estrogen-regulated CA 1 synaptic, 107
hippocampal
stress and, 105–18
neurotransmitter, 444–60
ocular dominance column, 305–8
stress-induced, 107–14
synaptic, 295–310
See also Synaptic plasticity
Posttraumatic stress disorder (PTSD), 116–17
Powell, Thomas PS, biography, 49–93
Alzheimer's disease studies of, 90–91
central olfactory connections studies, 67–71
cerebral cortex research
intrinsic connections, 87–88
pathways for sensory convergence, 49, 71–78
early studies with retrograde cellular degeneration, 52–55
electron microscopic studies, 49, 78–87
geniculocortical connections, 71–72
hippocampus research, 58–59, 69
thalamic connectivity studies, 53–57, 81–87
transneural degeneration research, 59–60
Premotor cortex, 324
Presynaptic facilitation, 443–48, 454–76
Presynaptic glutamate receptors, 465–71
Presynaptic inhibition, 443, 448–54
bipolar terminals of retina, 454
presynaptic ionotropic $GABA_A$ receptors and, 448
Presynaptic ionotropic receptors, 443–76
ATP-activated P2X receptors, 472–74
cyclic nucleotide-gated channels, 471–72
$GABA_A$ receptors and, 448–54
ionotropic receptors for serotonin (5HT3Rs), 475
mechanisms of regulation, 447
nicotinic acetylcholine and, 454–65, 475–76
presynaptic AMPA receptors, 465–68
presynaptic glutamate receptors, 465–71
presynaptic kainate receptors, 465–71
presynaptic NMDA receptors, 465–71
sources of neurotransmitter, 445–47
Protein kinase C, 6
Purkinje cells
cerebellar cortex formation and, 515–18
precursors of, 515

R

Rapsyn
agrin clustering and, 399–400
interactions with MuSK, 399–400
synapse elimination and, 414
Rasmussen's encephalitis, 185–87, 190
anti-GluR3 antibodies and, 185–87
membrane attack complex and, 187
Reaction time
saccade initiation and, 241, 251–56
countermanding paradigm, 253
target selection, 241, 255–56
Reactive oxygen species, 127–31
Parkinson's disease and, 127–31
Receptors
autoimmune response and calcium channel and, 180–83
glutamate (GluR3), 185–87
G-protein-coupled, 175, 188–89
metabotropic (mGluR1), 189
nicotinic cholinergic, 178–80
potassium channel and, 183–84
T-cell, 176
Receptor tyrosine kinases
Eph family of guidance receptors, 375–80
signal transduction by, 379–80
Recurrent depressive illness, 116–17
reeler mice, 511, 516–17, 525–27
Regeneration
synaptic, 389, 419–22
Reinnervation, 1, 6, 7
Remodeling
activity-dependent, 29–43
dorsal lateral geniculate nucleus (dLGN) and, 30–32, 37–41
visual system development, 30–43
Retina
bipolar terminals of, 454
developing, 29–43, 531
cell migration in, 531
synchronized activity, 29–43
dorsal lateral geniculate nucleus and, 30–32, 37–41
mechanisms underlying, 34–36
Retinal waves, 29–43
mechanisms underlying, 34–36
amacrine and, 35
glutamate and, 36
properties of, 32–34

Retrograde cellular degeneration, 50, 52–55, 58, 60
Rho-GTPases, 351, 354–64
  Cdc42, 354
  downstream targets, 358
  Mig-2, 354
  Rac, 354–59, 364
  Rho, 354–59
Ru49, 518–20

S

Saccade, 241–56
  latency, 242
  neural control of reaction time, 241, 251–53
  target selection, 241–51, 255–56
    experience and, 249–49
    frontal eye field and, 244
    neural correleates, 244
    timecourse, 249–51
    visual masking and, 247–48
    visual search, 245–47
Saccadic eye movements
  parietal cortex and, 319–47
    lateral intraparietal (LIP) area and, 321–22, 328–47
    remapping, 342–43, 346
Schizophrenia, 116–17
Schwann cells, 390–94
Selegiline, 138–39
  desmethyl, 138–39
    controlling Parkinson's disease with, 138–39
Sensory-to-motor coordinate transformation, 319
Serotonin, 106, 109, 475
  hippocampal plasticity and reversible atrophy of dendrites and, 109
  ionotropic receptors for, 475
Simian immunodeficiency virus, 224
Spatial representation, 319–47
  cochlea and, 319
  parietal cortex and, 319–47
    lateral intraparietal (LIP) area, 321–22, 328–47
    remapping, 342–43, 346
Speech
  See Birdsong; Human Speech; Vocalization
Spinal cord, 265–69, 282, 531
  cell migration in developing, 531
  cell patterning in dorsal, 265–69
Spinal motor neurons, 451–53
Stereotaxis, 72
Steroid hormones
  hippocampal plasticity and, 106–7
Stress
  hippocampal atrophy and, 114–18
    glucocorticoids and, 105, 114–18
  reversible atrophy of dendrites and, 107–12
    balance between neurogenesis and apoptosis in dentate gyrus and, 113–14
Stress-related disorders
  monoamine oxidase and, 29
Styryl dyes, 1–7
  synaptic transmission studies, 14–16
    FM1-43, 1–7
Substantia nigra
  Parkinson's disease and, 123, 127–30, 135–36
    glutathione deficiency, 127–29
    iron accumulation, 127–28
    mitochondrial dysfunction, 129–30, 135–36
    oxidative stress and, 127–28
Superantigen–T-cell interactions, 176
Sweat gland neurons, 555–60
Sympathetic neuron development, 541–60
  basic helix-loop-helix (bHLH), 543–44
    transcription factor MASH 1 and, 543–46
  glial cell line–derived neurotrophic factor (GDNF) and, 543
  model for neurotrophic regulation of, 553–54
  NGF and, 548–49
  NT-3 and, 549–51
  $p75^{NTR}$, 551–53
  sympathoadrenal progenitor (SA) and, 542–43
  sympathoenteric progenitor (SE) and, 542–48
    transient catecholaminergic precursors and, 543
  transient catecholaminergic (TC) cells and, 542–44
Sympathoadrenal (SA) progenitor, 542–43
Sympathoenteric (SE) progenitors
  environmental regulation of, 545–48
  sympathetic neuron development and, 542
    transient catecholaminergic precursors and, 543
Synapse
  elimination, 29–30, 389, 411–16
    synaptomedins and, 412, 414–15
    synaptotoxins, 412, 414, 416
    synaptotrophins, 412, 414, 416
  formation, 389–411, 422–28
    agrin and, 395–404
    calcitonin/gene-related peptide (CCRP), 400–1
    early, 393–95
    nerve-derived inducers of synapse-specific transcription, 400–1
    neuroregulin, 400–1
    specificity, 422–25
  maintenance, 389, 416–19
  regeneration, 389, 419–22
Synapsin I, 3
Synaptic plasticity
  neurotrophins and, 295–310
Synaptic transmission
  antibody modulation of, 175–92
  FM1-43, 1, 4–6
  styryl dye studies of, 1, 4–6
Synaptic vesicle
  endocytosis, 1–7
  exocytosis, 1–7
  recycling, 1–4
Synaptotagmin, 3
Synchronized activity, 29–43
  dorsal lateral geniculate nucleus and, 30–32, 37–41
  See also Retinal waves

T

Target selection, 241, 245–51, 255–56
  See also Gaze control
T-cell receptors
  superantigen–T-cell interactions, 176
Tetrodotoxin (TTX), 31–32, 461
Thalamostriatal projection, 54–57
Thalamus, 49, 54–57, 64–67
  electron microscopy, 81–83, 86–87
  thalamostriatal projection, 54–57
Thyrotropin releasing hormone, 7
Tight junctions, 11–25
  astrocytes and formation of, 15–17

blood-brain barrier and, 11–25
brain endothelial cell, 11–25
cyclic AMP levels, 17–18, 21
occcludin and, 11, 18–21, 23
p120 and, 22–23
Topographic maps, 49
Transferrin receptor, 12
Transforming growth factor-β
neural crest induction and, 262, 269, 272–73, 276–89
Transmitter release, 443–76
AFP-activated P2X receptors, 472–74
cyclic nucleotide-gated channels, 471–72
GABA and, 443–54
ionotropic receptors for, 475
presynaptic AMPA receptors, 465–68
presynaptic glutamate receptors, 465–71
presynaptic kainate receptors, 465–71
presynaptic nicotinic acetylcholine receptors and, 443, 445–65
autoreceptors, 460–61
heterosynaptic modulation, 461–63
presynaptic NMDA receptors, 465–71
Trypanosoma cruzi, 176, 188–89
Chagas' disease and, 176, 188–89
Tumor necrosis factor
α, 133, 221, 227
microglia and release of, 221, 227
β, 229
Tyrosine kinase receptors (trk), 296
trkA, 548–53
trkC, 551–53
Tyrosine phosphorylation, 21–22

V

Visual attention, 163–64
functional MRI and, 163–64
Visual connectivity
dorsal lateral geniculate nucleus (dLGN) and, 30–32, 37–41
ocular dominance columns, 31–32
retinal waves and, 29–43
synapse elimination and, 29–30
See also Retinal waves
Visual cortex, 145, 150–70
behavioral correlations, 150, 163–64
color perception and, 150, 161–63
dyslexia and, 145, 164, 170
functional MRI of, 145, 150–70
motion perception and, 145, 156–60
opponent-colors signals, 161–63, 170
retinotopy, 150–52
visual area identification, 150, 155–56
visual processing, 165–69
Visual search, 241–47
frontal eye field and, 244–47
target selection in, 245–47
Visual system
control of visually guided movements, 241–56
development
retinal waves and, 29–43
Vocalization, 567–621
audition and, 575–79
experience and, 584, 592, 614–17
hormones and, 614
innate predispositions, 579–84
learning in humans and songbirds, 573–79, 592–96, 609–19
neural mechanisms, 618–19
neural substrates for, 596–609
perception and, 592–96
social factors and, 617–18
Voltage-dependent calcium channel
blockade of
Lambert-Eaton myasthenic syndrome and, 180–83
specific channel proteins bound by immunoglobin G, 184
Voltage-dependent potassium channel
blockade of
autoantibodies and, 184
acquired neuromyotonia and, 183–84

W

Wnt
neural crest induction and, 261, 269–72, 280
Wound healing
FM dye studies of, 6, 7

X

Xenopus, 263–74
dorsal neural patterning in, 263–74

Y

Yeast
endocytosis in 1, 7
FM1-43 dye studies of, 1, 17
vacuole formation in, 1, 7

Z

Zellweger syndrome, 531–33